These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 8759643

  • 21. A new class of HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold.
    Ekegren JK, Unge T, Safa MZ, Wallberg H, Samuelsson B, Hallberg A.
    J Med Chem; 2005 Dec 15; 48(25):8098-102. PubMed ID: 16335934
    [Abstract] [Full Text] [Related]

  • 22. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
    Chen KX, Njoroge FG, Arasappan A, Venkatraman S, Vibulbhan B, Yang W, Parekh TN, Pichardo J, Prongay A, Cheng KC, Butkiewicz N, Yao N, Madison V, Girijavallabhan V.
    J Med Chem; 2006 Feb 09; 49(3):995-1005. PubMed ID: 16451065
    [Abstract] [Full Text] [Related]

  • 23. Development of pseudopeptide inhibitors of HIV-1 aspartic protease: analysis and tuning of the subsite specificity.
    Tossi A, Antcheva N, Romeo D, Miertus S.
    Pept Res; 1995 Feb 09; 8(6):328-34. PubMed ID: 8838416
    [Abstract] [Full Text] [Related]

  • 24. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency.
    Klabe RM, Bacheler LT, Ala PJ, Erickson-Viitanen S, Meek JL.
    Biochemistry; 1998 Jun 16; 37(24):8735-42. PubMed ID: 9628735
    [Abstract] [Full Text] [Related]

  • 25. Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against multidrug resistant HIV-1 strains.
    Tamamura H, Koh Y, Ueda S, Sasaki Y, Yamasaki T, Aoki M, Maeda K, Watai Y, Arikuni H, Otaka A, Mitsuya H, Fujii N.
    J Med Chem; 2003 Apr 24; 46(9):1764-8. PubMed ID: 12699395
    [Abstract] [Full Text] [Related]

  • 26. Anti-HIV triterpene acids from Geum japonicum.
    Xu HX, Zeng FQ, Wan M, Sim KY.
    J Nat Prod; 1996 Jul 24; 59(7):643-5. PubMed ID: 8759159
    [Abstract] [Full Text] [Related]

  • 27. Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysis.
    Nugiel DA, Jacobs K, Cornelius L, Chang CH, Jadhav PK, Holler ER, Klabe RM, Bacheler LT, Cordova B, Garber S, Reid C, Logue KA, Gorey-Feret LJ, Lam GN, Erickson-Viitanen S, Seitz SP.
    J Med Chem; 1997 May 09; 40(10):1465-74. PubMed ID: 9154969
    [Abstract] [Full Text] [Related]

  • 28. An orally bioavailable pyrrolinone inhibitor of HIV-1 protease: computational analysis and X-ray crystal structure of the enzyme complex.
    Smith AB, Hirschmann R, Pasternak A, Yao W, Sprengeler PA, Holloway MK, Kuo LC, Chen Z, Darke PL, Schleif WA.
    J Med Chem; 1997 Aug 01; 40(16):2440-4. PubMed ID: 9258349
    [No Abstract] [Full Text] [Related]

  • 29. Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold.
    Alterman M, Björsne M, Mühlman A, Classon B, Kvarnström I, Danielson H, Markgren PO, Nillroth U, Unge T, Hallberg A, Samuelsson B.
    J Med Chem; 1998 Sep 24; 41(20):3782-92. PubMed ID: 9748353
    [Abstract] [Full Text] [Related]

  • 30. Rapid discovery and structure-activity profiling of novel inhibitors of human immunodeficiency virus type 1 protease enabled by the copper(I)-catalyzed synthesis of 1,2,3-triazoles and their further functionalization.
    Whiting M, Tripp JC, Lin YC, Lindstrom W, Olson AJ, Elder JH, Sharpless KB, Fokin VV.
    J Med Chem; 2006 Dec 28; 49(26):7697-710. PubMed ID: 17181152
    [Abstract] [Full Text] [Related]

  • 31. Potent and selective inhibitors of human immunodeficiency virus protease structurally related to L-694,746.
    Franchetti P, Perlini P, Abu Sheikha G, Cappellacci L, Grifantini M, Loi AG, De Montis A, Pani A, Marongiu ME, La Colla P.
    Antivir Chem Chemother; 1998 Jul 28; 9(4):303-9. PubMed ID: 9875409
    [Abstract] [Full Text] [Related]

  • 32. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
    Jadhav PK, Woerner FJ, Lam PY, Hodge CN, Eyermann CJ, Man HW, Daneker WF, Bacheler LT, Rayner MM, Meek JL, Erickson-Viitanen S, Jackson DA, Calabrese JC, Schadt M, Chang CH.
    J Med Chem; 1998 Apr 23; 41(9):1446-55. PubMed ID: 9554878
    [Abstract] [Full Text] [Related]

  • 33. A series of potent HIV-1 protease inhibitors containing a hydroxyethyl secondary amine transition state isostere: synthesis, enzyme inhibition, and antiviral activity.
    Tucker TJ, Lumma WC, Payne LS, Wai JM, de Solms SJ, Giuliani EA, Darke PL, Heimbach JC, Zugay JA, Schleif WA.
    J Med Chem; 1992 Jul 10; 35(14):2525-33. PubMed ID: 1635054
    [Abstract] [Full Text] [Related]

  • 34. Synthesis of novel HIV protease inhibitors (PI) with activity against PI-resistant virus.
    Raghavan S, Lu Z, Beeson T, Chapman KT, Schleif WA, Olsen DB, Stahlhut M, Rutkowski CA, Gabryelski L, Emini E, Tata JR.
    Bioorg Med Chem Lett; 2007 Oct 01; 17(19):5432-6. PubMed ID: 17692518
    [Abstract] [Full Text] [Related]

  • 35. Design, synthesis and structure-activity study of shorter hexa peptide analogues as HIV-1 protease inhibitors.
    Narendra Babu SN, Rangappa KS.
    Bioorg Med Chem; 2008 Jan 15; 16(2):874-80. PubMed ID: 17981043
    [Abstract] [Full Text] [Related]

  • 36. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
    Frecer V, Burello E, Miertus S.
    Bioorg Med Chem; 2005 Sep 15; 13(18):5492-501. PubMed ID: 16054372
    [Abstract] [Full Text] [Related]

  • 37. CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity.
    Alteri E, Bold G, Cozens R, Faessler A, Klimkait T, Lang M, Lazdins J, Poncioni B, Roesel JL, Schneider P.
    Antimicrob Agents Chemother; 1993 Oct 15; 37(10):2087-92. PubMed ID: 8257128
    [Abstract] [Full Text] [Related]

  • 38. Synthesis of P1'-functionalized macrocyclic transition-state mimicking HIV-1 protease inhibitors encompassing a tertiary alcohol.
    De Rosa M, Unge J, Motwani HV, Rosenquist Å, Vrang L, Wallberg H, Larhed M.
    J Med Chem; 2014 Aug 14; 57(15):6444-57. PubMed ID: 25054811
    [Abstract] [Full Text] [Related]

  • 39. On the role of the R configuration of the reaction-intermediate isostere in HIV-1 protease-inhibitor binding: X-ray structure at 2.0 A resolution.
    Dusková J, Dohnálek J, Skálová T, Petroková H, Vondrácková E, Hradílek M, Konvalinka J, Soucek M, Brynda J, Fábry M, Sedlácek J, Hasek J.
    Acta Crystallogr D Biol Crystallogr; 2006 May 14; 62(Pt 5):489-97. PubMed ID: 16627941
    [Abstract] [Full Text] [Related]

  • 40. Two-carbon-elongated HIV-1 protease inhibitors with a tertiary-alcohol-containing transition-state mimic.
    Wu X, Ohrngren P, Ekegren JK, Unge J, Unge T, Wallberg H, Samuelsson B, Hallberg A, Larhed M.
    J Med Chem; 2008 Feb 28; 51(4):1053-7. PubMed ID: 18215014
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.